CONFIDENTIAL TREATMENT REQUESTED UNDER RULE 24B-2
UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
[*****] INDICATES OMITTED MATERIAL THAT IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST FILED SEPARATELY WITH THE COMMISSION. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE COMMISSION.
Control. This Agreement is made subject to any restrictions concerning the export of
products or technical information from the United States or other countries that may be imposed on the Parties from time to time.
Each Party agrees that it will not export, directly or indirectly, any technical information acquired from the other Party under
this Agreement or any products using such technical information to a location or in a manner that at the time of export requires
an export license or other governmental approval, without first obtaining the written consent to do so from the appropriate agency
or other Governmental Authority in accordance with Applicable Law.
Party may, directly or indirectly, assign or otherwise transfer this Agreement or its rights or obligations under this Agreement,
in whole or in part, without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned
or delayed, provided, however, that:
may assign or otherwise transfer this Agreement or its rights or obligations under this Agreement, in whole or in part, without
Lilly’s consent (a) in connection with the transfer or sale of all or substantially all of the assets of ACI to a Third
Party, whether by merger, sale of stock, sale of assets or otherwise, provided that such Third Party agrees to be bound
by, and assumes and succeeds to, all of the obligations of ACI under this Agreement or (b) to an Affiliate, provided that
ACI shall remain liable and responsible to Lilly for the performance and observance of all such obligations by such Affiliate;
may, upon prior written notice to ACI, assign or otherwise transfer this Agreement or its rights or obligations under this Agreement,
in whole or in part, without ACI’s consent, (a) in connection with the transfer or sale of all or substantially all of the
neurodegenerative business of Lilly to any Major Pharmaceutical Company, (b) to an Affiliate, provided that Lilly
shall remain liable and responsible to ACI for the performance and observance of all such obligations by such Affiliate.
anything in this Agreement to the contrary, in the event that either Party assigns or otherwise transfers this Agreement to any
of such Party’s Affiliates, any Change of Control of any such Affiliate shall be deemed to be an assignment of this Agreement
for the purposes of, and subject to, this Section 13.3.1. This Agreement will be binding upon and inure to the benefit of
the Parties and their successors and permitted assigns. Any attempted assignment or delegation in violation of this Section 13.3.1
shall be void and of no effect.